Search | Clinical Trials Finder

Conditions: Migraine in Children, Sphenopalatine Neuralgia, Migraine in Adolescence
Interventions: Lidocaine topical, Prochlorperazine Injection; Drug
Lead sponsor: Newark Beth Israel Medical Center; Other
Eligibility: 10 Years to 20 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Head and Neck Cancer
Interventions: Capecitabine, Oxaliplatin; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Gingival Recession
Interventions: enamel matrix derivative, Porcine collagen matrix; Biological · Device
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 30 participants
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cancer
Interventions: trastuzumab, tipifarnib; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 2
States / cities: Fort Sam Houston, Texas • San Antonio, Texas

Conditions: Oral Lichen Planus
Interventions: Clobetasol Propionate; Drug
Lead sponsor: Dermtreat; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 14
States / cities: Hialeah, Florida • Miami, Florida • Augusta, Georgia + 8 more

Conditions: Acute Gastrointestinal Graft vs Host Disease
Interventions: oral beclomethasone 17,21-dipropionate, Placebo; Drug
Lead sponsor: Soligenix; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 3
States / cities: Buffalo, New York • Durham, North Carolina • Seattle, Washington

Conditions: Acute Myeloid Leukemia
Interventions: Planned Chemotherapy; Other
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Fallopian Tube Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: ILX-295501; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 120 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 8
States / cities: Los Angeles, California • Indianapolis, Indiana • Baltimore, Maryland + 5 more

Conditions: Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm, Stomatitis
Interventions: Anti-inflammatory/Antimicrobial/Analgesic Aqueous Mouth Rinse, Methylene Blue Oral Rinse; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Alzheimer's Disease
Interventions: Ketasyn; Other
Lead sponsor: Cerecin; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Parkinson's Disease (PD)
Interventions: ABBV-951, Placebo for Levodopa/Carbidopa (LD/CD), Levodopa/Carbidopa (LD/CD), Placebo for ABBV-951; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 30 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 70
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 62 more

Conditions: Retinitis Pigmentosa
Interventions: Hydroxychloroquine lower dose, Hydroxychloroquine higher dose; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Sjogren's Syndrome
Interventions: Tofacitinib; Drug
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Renal Anemia
Interventions: AND017, Placebo; Drug
Lead sponsor: Kind Pharmaceuticals LLC; Industry
Eligibility: 20 Years to 74 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 7
States / cities: Northridge, California • Winter Park, Florida • Shreveport, Louisiana + 4 more

Conditions: Head Cancer, Neck Cancer, Pain
Interventions: Transcutaneous Electrical Nerve Stimulation (TENS); Device
Lead sponsor: Jennifer E. Lee; Other
Eligibility: 18 Years to 90 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Chronic Kidney Diseases, Pruritus
Interventions: Difelikefalin 1 mg Oral Tablet, Placebo Oral Tablet; Drug
Lead sponsor: Cara Therapeutics, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 83
States / cities: Huntsville, Alabama • Phoenix, Arizona • Surprise, Arizona + 76 more

Conditions: Oral Cavity Cancer, Oropharynx Cancer, Hypopharynx Cancer, Larynx Cancer
Interventions: ENHANCE Intervention - Exercise and Nutrition, ENHANCE Intervention - Nutrition Only; Behavioral
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Iron Deficiency Anaemia, Chronic Kidney Disease
Interventions: FCM (Ferric carboxymaltose) high ferritin target, FCM (Ferric carboxymaltose) low ferritin target, Oral Iron (Ferrous sulphate); Drug
Lead sponsor: Vifor Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 626 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Head and Neck
Interventions: Hydroxyurea, 5- Fluorouracil, Cisplatin; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 59 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Primary Sjögren's Syndrome
Interventions: S95011 concentrate for solution for infusion, Placebo concentrate for solution for infusion; Drug
Lead sponsor: Institut de Recherches Internationales Servier; Other
Eligibility: 18 Years to 75 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Lakewood, Colorado • Duncansville, Pennsylvania

Conditions: Severe Periodontitis
Interventions: Valacyclovir group, Control group; Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Glioblastoma Multiforme, Squamous Cell Carcinoma of Head and Neck, Prostate Cancer, Ewing's Osteosarcoma, Chronic Lymphocytic Leukemia, Neoplasm Metastasis
Interventions: CC-115; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 10
States / cities: Los Angeles, California • San Francisco, California • Tampa, Florida + 6 more

Conditions: Urothelial Carcinoma, Urothelial Carcinoma Bladder, Bladder Cancer, Bladder Disease, Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, Metastatic Cancer, Advanced Solid Tumor, Advanced Cancer, Metastatic Bladder Cancer, Metastatic Urothelial Carcinoma, Locally Advanced Solid Tumor, Neoplasms, Neoplasm Metastasis, Neoplasm Malignant, Neoplasm, Bladder, Urothelial Neoplasm, Neoplasm, Urinary Bladder, Bladder Neoplasm, Bladder Urothelial Carcinoma
Interventions: IK-175, IK-175 and nivolumab; Drug
Lead sponsor: Ikena Oncology; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 10
States / cities: Gilbert, Arizona • Sarasota, Florida • Chicago, Illinois + 7 more

Conditions: Crohn's Disease, Ulcerative Colitis
Interventions: Zasocitinib; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Glen Burnie, Maryland • Tyler, Texas

Search by objective public record fields.

SPG Block for Acute Pediatric Migraine

Title XELOX FOR SALIVARY GLAND CANCERS

Collagen Matrix With and Without Enamel Matrix Derivative

Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

Intra-oral Treatment of OLP With Rivelin®-CLO Patches

Study of orBec® With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)

Study of Periodontitis and Blood Stream Infection in AML Patients Receiving Chemotherapy

ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment

Methylene Blue Mouthwash for the Treatment of Oral Mucositis Pain in Patients With Cancer

Safety of Three Formulations of Ketasyn Administered for 14 Days in Healthy Elderly

Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease

Oral Hydroxychloroquine (HCQ) for Retinitis Pigmentosa Caused by P23H- Rhodopsin (RHO)

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease

A Study of AND017 to Treat Anemia in Non-dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients

Transcutaneous Electrical Nerve Stimulation (TENS) and Head and Neck Cancer Pain (HNC) (TENS & HNC)

A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

The ENHANCE Study: Exercise and Nutrition in Head And Neck CancEr Survivors

Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

A Multicenter Study of Intensive Concomitant Chemoradiotherapy With Filgrastim (GCSF) for Patients With Locoregionally Advanced Head and Neck Cancer

Efficacy and Safety of S95011 in Primary Sjögren's Syndrome Patients

The Efficacy of Systemic Valacyclovir (Valtrex) on Periodontitis

Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.

A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma

A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)